Cargando…

VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension

BACKGROUND: Pulmonary Arterial Hypertension (PAH) remains a therapeutic challenge, and the search continues for more effective drugs and drug combinations. We recently reported that deletion of the vasoactive intestinal peptide (VIP) gene caused the spontaneous expression of a PH phenotype that was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamidi, Sayyed A, Lin, Richard Z, Szema, Anthony M, Lyubsky, Sergey, Jiang, Ya Ping, Said, Sami I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210095/ https://www.ncbi.nlm.nih.gov/pubmed/22029879 http://dx.doi.org/10.1186/1465-9921-12-141

Ejemplares similares

VIP Gene Deletion in Mice Causes Cardiomyopathy Associated with Upregulation of Heart Failure Genes
por: Szema, Anthony M., et al.
Publicado: (2013)

VIP Regulates the Development & Proliferation of Treg in vivo in spleen
por: Szema, Anthony M, et al.
Publicado: (2011)

Vasoactive Intestinal Peptide Knockout (VIP KO) mouse model of sulfite-sensitive asthma: up-regulation of novel lung carbonyl reductase
por: Szema, Anthony M, et al.
Publicado: (2011)

NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease
por: Szema, Anthony M., et al.
Publicado: (2017)

Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension
por: Droste, Annette S, et al.
Publicado: (2009)

Pharmacogenomics in pulmonary arterial hypertension: Toward a mechanistic, target-based approach to therapy
por: Said, Sami I., et al.
Publicado: (2011)

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension
por: Steiner, M Kathryn, et al.
Publicado: (2008)

Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?
por: Badagliacca, Roberto, et al.
Publicado: (2020)

Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
por: Correale, Michele, et al.
Publicado: (2018)

Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
por: Tynan, Timothy, et al.
Publicado: (2019)

Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
por: Belge, Catharina, et al.
Publicado: (2019)

The role of endothelin-1 in pulmonary arterial hypertension
por: Chester, Adrian H., et al.
Publicado: (2014)

Endothelin Receptors and Their Antagonists()()
por: Maguire, Janet J., et al.
Publicado: (2015)

Endothelin B Receptor Immunodynamics in Pulmonary Arterial Hypertension
por: Tabeling, Christoph, et al.
Publicado: (2022)

The safety of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension: Protocol for a systemic review and network meta-analysis
por: Gu, Zhi-Chun, et al.
Publicado: (2018)

Current Status of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension: A Combined Study Results and Pharmacology-Based Review
por: Nahar, Shamsun, et al.
Publicado: (2023)

Endothelin and Endothelin Antagonists in Chronic Kidney Disease
por: Kohan, Donald E., et al.
Publicado: (2014)

Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis
por: Cao, Fen, et al.
Publicado: (2023)

Insights into Endothelin Receptors in Pulmonary Hypertension
por: Liu, Ruiqi, et al.
Publicado: (2023)

The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis
por: Kuang, Hong-Yu, et al.
Publicado: (2018)

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
por: Opitz, Christian F., et al.
Publicado: (2008)

Endothelin-1 Predicts Hemodynamically Assessed Pulmonary Arterial Hypertension in HIV Infection
por: Parikh, Rushi V., et al.
Publicado: (2016)

The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross‐species comparison of its cytochrome P450 induction pattern
por: Treiber, Alexander, et al.
Publicado: (2020)

Idiopathic pre-capillary pulmonary hypertension in patients with end-stage kidney disease: effect of endothelin receptor antagonists
por: Nishimura, Masato, et al.
Publicado: (2016)

Pipersentan: A De Novo Synthetic Endothelin Receptor Antagonist that Inhibits Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension
por: Zhang, Zeyu, et al.
Publicado: (2022)

The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and Sepsis
por: Kowalczyk, Agata, et al.
Publicado: (2014)

Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors
por: Frantz, Robert P., et al.
Publicado: (2020)

Distortion of K(B) estimates of endothelin‐1 ET(A) and ET(B) receptor antagonists in pulmonary arteries: Possible role of an endothelin‐1 clearance mechanism
por: Angus, James A., et al.
Publicado: (2017)

Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension
por: Kuc, Rhoda E., et al.
Publicado: (2014)

Endothelin Receptor Antagonists in Kidney Disease
por: Martínez-Díaz, Irene, et al.
Publicado: (2023)

Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension
por: Carratu, Pierluigi, et al.
Publicado: (2008)

Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension
por: Verweij, Pierre, et al.
Publicado: (2020)

Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
por: Angeli, Fabio, et al.
Publicado: (2021)

Unraveling endothelin-1 induced hypercontractility of human pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension
por: Wilson, Jamie L., et al.
Publicado: (2018)

Endothelin ET(A) receptors predominate in chronic thromboembolic pulmonary hypertension
por: Southwood, Mark, et al.
Publicado: (2016)

Lung Function, Inflammation, and Endothelin‐1 in Congenital Heart Disease–Associated Pulmonary Arterial Hypertension
por: Low, Andrew, et al.
Publicado: (2018)

Role of Endothelin-1 in Right Atrial Arrhythmogenesis in Rabbits with Monocrotaline-Induced Pulmonary Arterial Hypertension
por: Lu, Yen-Yu, et al.
Publicado: (2022)

Antidiuretic Effects of the Endothelin Receptor Antagonist Avosentan
por: Baltatu, Ovidiu Constantin, et al.
Publicado: (2012)

Iontophoresis of Endothelin Receptor Antagonists in Rats and Men
por: Roustit, Matthieu, et al.
Publicado: (2012)

Endothelin antagonists in subarachnoid hemorrhage: what next?
por: Macdonald, R Loch
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_46ph4dh7v5o15qgmfq989j8ihe